Skip to main content

Advertisement

Articles

Page 5 of 23

  1. Content type: Correction

    The original article [1] contained incorrect affiliations for the authors.

    Authors: Chun-Hua Wei, Gang Wu, Qian Cai, Xi-Can Gao, Fan Tong, Rui Zhou, Rui-Guang Zhang, Ji-Hua Dong, Yu Hu and Xiao-Rong Dong

    Citation: Journal of Hematology & Oncology 2018 11:6

    Published on:

    The original article was published in Journal of Hematology & Oncology 2017 10:125

  2. Content type: Correction

    The original article [1] contains two errors in Table 2

    Authors: Xinyang Liu, Shukui Qin, Zhichao Wang, Jianming Xu, Jianping Xiong, Yuxian Bai, Zhehai Wang, Yan Yang, Guoping Sun, Liwei Wang, Leizhen Zheng, Nong Xu, Ying Cheng, Weijian Guo, Hao Yu, Tianshu Liu…

    Citation: Journal of Hematology & Oncology 2018 11:5

    Published on:

    The original article was published in Journal of Hematology & Oncology 2017 10:153

  3. Content type: Research

    Novel therapies for patients with acute myeloid leukemia (AML) are imperative, particularly for those with high-risk features. Selinexor, an exportin 1 (XPO1/CRM1) inhibitor, has demonstrated anti-leukemia act...

    Authors: Amy Y. Wang, Howard Weiner, Margaret Green, Hua Chang, Noreen Fulton, Richard A. Larson, Olatoyosi Odenike, Andrew S. Artz, Michael R. Bishop, Lucy A. Godley, Michael J. Thirman, Satyajit Kosuri, Jane E. Churpek, Emily Curran, Kristen Pettit, Wendy Stock…

    Citation: Journal of Hematology & Oncology 2018 11:4

    Published on:

  4. Content type: Review

    Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease. Despite advances in understanding the pathogenesis of AML, the standard therapy remained nearly unchanged over the past three...

    Authors: Xue Yang and Jianxiang Wang

    Citation: Journal of Hematology & Oncology 2018 11:3

    Published on:

  5. Content type: Retraction Note

    The authors have retracted this article [1] because of significant overlap of text and some images with a previously published article by Xu et al. [2]. A formal investigation by the 1st Affiliated Hospital of...

    Authors: Yu Fan, Yan-fen Wang, Hua-fang Su, Na Fang, Chen Zou, Wen-feng Li and Zheng-hua Fei

    Citation: Journal of Hematology & Oncology 2018 11:2

    Published on:

    The original article was published in Journal of Hematology & Oncology 2016 9:57

  6. Content type: Research

    Chimeric antigen receptor (CAR)-engineered T cells have demonstrated promising clinical efficacy in patients with B cell lymphoma. However, the application of CAR-T cell therapy in the treatment of other solid...

    Authors: Jiayi Yu, Xiaowen Wu, Junya Yan, Huan Yu, Longwen Xu, Zhihong Chi, Xinan Sheng, Lu Si, Chuanliang Cui, Jie Dai, Meng Ma, Tianxiao Xu, Yan Kong and Jun Guo

    Citation: Journal of Hematology & Oncology 2018 11:1

    Published on:

  7. Content type: Review

    Liquid biopsy especially that of exosomes carries tumor-specific molecules and provides useful information during tumor development and progression in “real time.” Exosomes are membrane-encapsulated vesicles, ...

    Authors: Aichun Li, Tianbao Zhang, Min Zheng, Yanning Liu and Zhi Chen

    Citation: Journal of Hematology & Oncology 2017 10:175

    Published on:

  8. Content type: Research

    Liposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease. The Achilles heel of cancer often is their kinases that are ex...

    Authors: Deepika Kanojia, Manoj Garg, Jacqueline Martinez, Anand M.T., Samuel B. Luty, Ngan B. Doan, Jonathan W. Said, Charles Forscher, Jeffrey W. Tyner and H. Phillip Koeffler

    Citation: Journal of Hematology & Oncology 2017 10:173

    Published on:

  9. Content type: Research

    The tyrosine kinase Src is involved in the progression of many cancers. Moreover, inhibiting Src activity has been shown to obstruct several signaling pathways regulated by the EGFR. Thus, Src is a valuable ta...

    Authors: Yi-Hua Lai, Sih-Yin Lin, Yu-Shan Wu, Huei-Wen Chen and Jeremy J. W. Chen

    Citation: Journal of Hematology & Oncology 2017 10:172

    Published on:

  10. Content type: Research

    The observational MCL-004 study evaluated outcomes in patients with relapsed/refractory mantle cell lymphoma who received lenalidomide-based therapy after ibrutinib failure or intolerance.

    Authors: Michael Wang, Stephen J. Schuster, Tycel Phillips, Izidore S. Lossos, Andre Goy, Simon Rule, Mehdi Hamadani, Nilanjan Ghosh, Craig B. Reeder, Evelyn Barnett, Marie-Laure Casadebaig Bravo and Peter Martin

    Citation: Journal of Hematology & Oncology 2017 10:171

    Published on:

  11. Content type: Research

    Cholangiocarcinoma (CCA) is characterized by early lymphatic, metastasis, and low survival rate. Epithelial-mesenchymal transition (EMT) is able to induce tumor metastasis. Although the TGF-β/miR-200 signals p...

    Authors: Dawei Zhang, Haiyan Li, Xiaofeng Jiang, Liangqi Cao, Zilong Wen, Xuewei Yang and Ping Xue

    Citation: Journal of Hematology & Oncology 2017 10:170

    Published on:

  12. Content type: Review

    The molecular mechanisms underlying dysregulated wild type (wt) p53 in multiple myeloma (MM) have been subjects of intense investigation for years. Indeed, correlation of rarely occurring TP53 gene mutations or d...

    Authors: Jahangir Abdi, Nasrin Rastgoo, Lihong Li, Wenming Chen and Hong Chang

    Citation: Journal of Hematology & Oncology 2017 10:169

    Published on:

  13. Content type: Research

    Nuclear receptors (NRs) can regulate gene expression; therefore, they are classified as transcription factors. Despite the extensive research carried out on NRs, still several issues including (1) the expressi...

    Authors: Luqiao Wang, Gayani Nanayakkara, Qian Yang, Hongmei Tan, Charles Drummer, Yu Sun, Ying Shao, Hangfei Fu, Ramon Cueto, Huimin Shan, Teodoro Bottiglieri, Ya-feng Li, Candice Johnson, William Y. Yang, Fan Yang, Yanjie Xu…

    Citation: Journal of Hematology & Oncology 2017 10:168

    Published on:

  14. Content type: Rapid communication

    Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-spe...

    Authors: Bingshan Liu, Yongping Song and Delong Liu

    Citation: Journal of Hematology & Oncology 2017 10:166

    Published on:

  15. Content type: Review

    T cells recognize antigen fragments from proteolytic products that are presented to them in the form of peptides on major histocompatibility complex (MHC) molecules, which is crucial for the T cell to identify...

    Authors: Liangshun You, Liping Mao, Juying Wei, Shenhe Jin, Chunmei Yang, Hui Liu, Li Zhu and Wenbin Qian

    Citation: Journal of Hematology & Oncology 2017 10:165

    Published on:

  16. Content type: Review

    Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and secondary resistance to currently available therapies in most cases. Therefore, despite recent advances in the treatment of this...

    Authors: Michael Fichtner, Martin Dreyling, Mascha Binder and Martin Trepel

    Citation: Journal of Hematology & Oncology 2017 10:164

    Published on:

  17. Content type: Research

    Xenotransplantation of patient-derived AML (acute myeloid leukemia) cells in NOD-scid Il2rγ null (NSG) mice is the method of choice for evaluatin...

    Authors: Zhisheng Her, Kylie Su Mei Yong, Kathirvel Paramasivam, Wilson Wei Sheng Tan, Xue Ying Chan, Sue Yee Tan, Min Liu, Yong Fan, Yeh Ching Linn, Kam Man Hui, Uttam Surana and Qingfeng Chen

    Citation: Journal of Hematology & Oncology 2017 10:162

    Published on:

  18. Content type: Research

    EPH (erythropoietin-producing hepatocellular) receptors are clinically relevant targets in several malignancies. This report describes the effects of GLPG1790, a new potent pan-EPH inhibitor, in human embryona...

    Authors: Francesca Megiorni, Giovanni Luca Gravina, Simona Camero, Simona Ceccarelli, Andrea Del Fattore, Vincenzo Desiderio, Federica Papaccio, Heather P. McDowell, Rajeev Shukla, Antonio Pizzuti, Filip Beirinckx, Philippe Pujuguet, Laurent Saniere, Ellen Van der Aar, Roberto Maggio, Francesca De Felice…

    Citation: Journal of Hematology & Oncology 2017 10:161

    Published on:

  19. Content type: Erratum

    Authors: Eddy C. Hsueh, James R. DeBloom, Jonathan Lee, Jeffrey J. Sussman, Kyle R. Covington, Brooke Middlebrook, Clare Johnson, Robert W. Cook, Craig L. Slingluff Jr and Kelly M. McMasters

    Citation: Journal of Hematology & Oncology 2017 10:160

    Published on:

    The original article was published in Journal of Hematology & Oncology 2017 10:152

  20. Content type: Research

    The stem cell factor spalt-like transcription factor 4 (SALL4) plays important roles in normal hematopoiesis and also in leukemogenesis. We previously reported that SALL4 exerts its effect by recruiting import...

    Authors: Lina Yang, Li Liu, Hong Gao, Jaya Pratap Pinnamaneni, Deepthi Sanagasetti, Vivek P. Singh, Kai Wang, Megumi Mathison, Qianzi Zhang, Fengju Chen, Qianxing Mo, Todd Rosengart and Jianchang Yang

    Citation: Journal of Hematology & Oncology 2017 10:159

    Published on:

  21. Content type: Research

    Multiple primary cancers (MPC) have been identified as two or more cancers without any subordinate relationship that occur either simultaneously or metachronously in the same or different organs of an individu...

    Authors: Hai Hu, Hong Li, Feng Jiao, Ting Han, Meng Zhuo, Jiujie Cui, Yixue Li and Liwei Wang

    Citation: Journal of Hematology & Oncology 2017 10:158

    Published on:

  22. Content type: Review

    Multiple myeloma (MM) is a malignant tumor of transformed plasma cells. MM pathogenesis is a multistep process. This cancer can occur de novo (rarely) or it can develop from monoclonal gammopathy of undetermin...

    Authors: Sabrina Manni, Marilena Carrino and Francesco Piazza

    Citation: Journal of Hematology & Oncology 2017 10:157

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2018 11:51

  23. Content type: Research

    Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a J...

    Authors: Srdan Verstovsek, Jason Gotlib, Ruben A. Mesa, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, Claire N. Harrison, Ronald Paquette, William Sun, Ahmad Naim, Peter Langmuir, Tuochuan Dong, Prashanth Gopalakrishna and Vikas Gupta

    Citation: Journal of Hematology & Oncology 2017 10:156

    Published on:

  24. Content type: Review

    Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T), bispecific antibody (BsAb) is attracting more and mo...

    Authors: Shengnan Yu, Anping Li, Qian Liu, Xun Yuan, Hanxiao Xu, Dechao Jiao, Richard G. Pestell, Xinwei Han and Kongming Wu

    Citation: Journal of Hematology & Oncology 2017 10:155

    Published on:

  25. Content type: Erratum

    Authors: Francine Foss, Steven Horwitz, Barbara Pro, H. Miles Prince, Lubomir Sokol, Barbara Balser, Julie Wolfson and Bertrand Coiffier

    Citation: Journal of Hematology & Oncology 2017 10:154

    Published on:

    The original article was published in Journal of Hematology & Oncology 2016 9:22

  26. Content type: Short report

    Reliable biomarkers of apatinib response in gastric cancer (GC) are lacking. We investigated the association between early presence of common adverse events (AEs) and clinical outcomes in metastatic GC patients.

    Authors: Xinyang Liu, Shukui Qin, Zhichao Wang, Jianming Xu, Jianping Xiong, Yuxian Bai, Zhehai Wang, Yan Yang, Guoping Sun, Liwei Wang, Leizhen Zheng, Nong Xu, Ying Cheng, Weijian Guo, Hao Yu, Tianshu Liu…

    Citation: Journal of Hematology & Oncology 2017 10:153

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2018 11:5

  27. Content type: Research

    A 31-gene expression profile (GEP) test that provides risk classification of cutaneous melanoma (CM) patients has been validated in several retrospective studies. The objective of the reported study was a pros...

    Authors: Eddy C. Hsueh, James R. DeBloom, Jonathan Lee, Jeffrey J. Sussman, Kyle R. Covington, Brooke Middlebrook, Clare Johnson, Robert W. Cook, Craig L. Slingluff Jr and Kelly M. McMasters

    Citation: Journal of Hematology & Oncology 2017 10:152

    Published on:

    The Erratum to this article has been published in Journal of Hematology & Oncology 2017 10:160

  28. Content type: Review

    Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success ...

    Authors: Mingxue Fan, Minghao Li, Lipeng Gao, Sicong Geng, Jing Wang, Yiting Wang, Zhiqiang Yan and Lei Yu

    Citation: Journal of Hematology & Oncology 2017 10:151

    Published on:

  29. Content type: Review

    Gastric cancer is the third most common cause of cancer death worldwide, although it is not in the top 10 causes of cancer death in Northern America. Due to clear differences in incidence, screening, risk fact...

    Authors: Brian Badgwell, Prajnan Das and Jaffer Ajani

    Citation: Journal of Hematology & Oncology 2017 10:149

    Published on:

  30. Content type: Research

    Structural chromosomal rearrangements that lead to expressed fusion genes are a hallmark of acute lymphoblastic leukemia (ALL). In this study, we performed transcriptome sequencing of 134 primary ALL patient s...

    Authors: Yanara Marincevic-Zuniga, Johan Dahlberg, Sara Nilsson, Amanda Raine, Sara Nystedt, Carl Mårten Lindqvist, Eva C. Berglund, Jonas Abrahamsson, Lucia Cavelier, Erik Forestier, Mats Heyman, Gudmar Lönnerholm, Jessica Nordlund and Ann-Christine Syvänen

    Citation: Journal of Hematology & Oncology 2017 10:148

    Published on:

  31. Content type: Review

    Gastrointestinal (GI) malignancies are the most prevalent tumors worldwide, with increasing incidence and mortality. Although surgical resection, chemotherapy, radiotherapy, and molecular targeted therapy have...

    Authors: Junyu Long, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, Haifeng Xu, Shuguang Chen and Haitao Zhao

    Citation: Journal of Hematology & Oncology 2017 10:146

    Published on:

  32. Content type: Review

    Cancer is caused by uncontrollable growth of neoplastic cells, leading to invasion of adjacent and distant tissues resulting in death. Cancer cells have specific nutrient(s) auxotrophy and have a much higher n...

    Authors: Marcus Kwong Lam Fung and Godfrey Chi-Fung Chan

    Citation: Journal of Hematology & Oncology 2017 10:144

    Published on:

  33. Content type: Erratum

    Authors: Ming-de Huang, Wen-ming Chen, Fu-zhen Qi, Rui Xia, Ming Sun, Tong-peng Xu, Li Yin, Er-bao Zhang, Wei De and Yong-qian Shu

    Citation: Journal of Hematology & Oncology 2017 10:143

    Published on:

    The original article was published in Journal of Hematology & Oncology 2015 8:57

    The original article was published in Journal of Hematology & Oncology 2015 8:50

  34. Content type: Review

    The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer treatment in the past decade, both in oncology and hematology. The transfer of the immunotherapeutic concepts to the tr...

    Authors: Felix S. Lichtenegger, Christina Krupka, Sascha Haubner, Thomas Köhnke and Marion Subklewe

    Citation: Journal of Hematology & Oncology 2017 10:142

    Published on:

  35. Content type: Review

    Adaptive immunity is critical for disease progression and modulates T cell (TC) and antigen-presenting cell (APC) functions. Three signals were initially proposed for adaptive immune activation: signal 1 antig...

    Authors: Jin Dai, Pu Fang, Jason Saredy, Hang Xi, Cueto Ramon, William Yang, Eric T. Choi, Yong Ji, Wei Mao, Xiaofeng Yang and Hong Wang

    Citation: Journal of Hematology & Oncology 2017 10:141

    Published on:

  36. Content type: Research

    Understanding the molecular/cellular underpinnings of diffuse malignant peritoneal mesothelioma (DMPM), a fatal malignancy with limited therapeutic options, is of utmost importance for the fruitful management ...

    Authors: Graziella Cimino-Reale, Paolo Gandellini, Francesca Santambrogio, Marta Recagni, Nadia Zaffaroni and Marco Folini

    Citation: Journal of Hematology & Oncology 2017 10:140

    Published on:

  37. Content type: Research

    Additional sex combs-like 1 (ASXL1) is frequently mutated in myeloid malignancies. Recent studies showed that hematopoietic-specific deletion of Asxl1 or overexpression of mutant ASXL1

    Authors: Yueh-Chwen Hsu, Yu-Chiao Chiu, Chien-Chin Lin, Yuan-Yeh Kuo, Hsin-An Hou, Yi-Shiuan Tzeng, Chein-Jun Kao, Po-Han Chuang, Mei-Hsuan Tseng, Tzu-Hung Hsiao, Wen-Chien Chou and Hwei-Fang Tien

    Citation: Journal of Hematology & Oncology 2017 10:139

    Published on:

  38. Content type: Research

    Current conventional chemotherapy for acute myeloid leukemia (AML) can achieve remission in over 70% of patients, but a majority of them will relapse within 5 years despite continued treatment. The relapse is ...

    Authors: Jianbiao Zhou, Chonglei Bi, Ying Qing Ching, Jing-Yuan Chooi, Xiao Lu, Jessie Yiying Quah, Sabrina Hui-Min Toh, Zit-Liang Chan, Tuan Zea Tan, Phyllis SY Chong and Wee-Joo Chng

    Citation: Journal of Hematology & Oncology 2017 10:138

    Published on:

  39. Content type: Research

    The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide–dexamethasone (Rd) in pat...

    Authors: Jian Hou, Jie Jin, Yan Xu, Depei Wu, Xiaoyan Ke, Daobin Zhou, Jin Lu, Xin Du, Xiequn Chen, Junmin Li, Jing Liu, Neeraj Gupta, Michael J. Hanley, Hongmei Li, Zhaowei Hua, Bingxia Wang…

    Citation: Journal of Hematology & Oncology 2017 10:137

    Published on:

  40. Content type: Research

    Granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (G-PBSC) has largely replaced unstimulated bone marrow (un-BM) for allografting because of accelerated engraftment, but with ...

    Authors: Qian Fan, Hui Liu, Xinquan Liang, Ting Yang, Zhiping Fan, Fen Huang, Yiwen Ling, Xin Liao, Li Xuan, Na Xu, Xiaojun Xu, Jieyu Ye and Qifa Liu

    Citation: Journal of Hematology & Oncology 2017 10:135

    Published on:

  41. Content type: Research

    This study compared the effects of pre-transplantation minimal residual disease (pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched sibling donor transplantation (MSDT) or who r...

    Authors: Ying-Jun Chang, Yu Wang, Yan-Rong Liu, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Kai-Yan Liu and Xiao-Jun Huang

    Citation: Journal of Hematology & Oncology 2017 10:134

    Published on:

  42. Content type: Review

    The two murine double minute (MDM) family members MDM2 and MDMX are at the center of an intense clinical assessment as molecular target for the management of cancer. Indeed, the two proteins act as regulators ...

    Authors: Veronica Tisato, Rebecca Voltan, Arianna Gonelli, Paola Secchiero and Giorgio Zauli

    Citation: Journal of Hematology & Oncology 2017 10:133

    Published on:

JHO logo

Annual Journal Metrics

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here

Advertisement